

European Society for Blood and Marrow Transplantation

Infectious Diseases Working Party

Chair: Rafael de la Camara Former chair: Jan Styczynski

Secretary: Dina Averbuch

Statistician: Gloria Tridello

IDWP in 2019

MISSION

Mission of IDWP is to share the experience and develop cooperative studies to increase the knowledge in the field of diagnosis, prophylaxis and treatment of infectious complications in HSCT patients.

MAYOR ACHIEVEMENTS

IDWP Members continue their scientific and educational activity in the fields of: bacterial infections, viral infections, fungal infections, including Pneumocystis jirovecii, parasitic infections, vaccinations, protective environment and guidelines development.

IDWP at EBMT Annual Meeting

IDWP PRESENTATIONS

(Saturday 29 August, time 15.00-16.00)

INFECTIOUS COMPLICATIONS: NEW THERAPIES AND PREVENTION

• Dina Averbuch (Israel): Multiresistant bacteria in children and adults: insight on new antibiotics

IDWP recent achievements were published in *Lancet Infectious Diseases, Haematologica, Journal of Antimicrobial Chemotherapy*, and *Bone Marrow Transplantation*.

PRINCIPLE RESEARCH STUDIES

ONGOING RETROSPECTIVE PROJECTS INCLUDE:

(1) Nocardia Invasive Infections post-HSCT, (2) Listeria infections after HSCT,(3) Human metapneumovirus post-HSCT

ONGOING PROSPECTIVE NON-INTERVENTIONAL PROJECTS INCLUDE:

(1) Impact of Covid-19 on stem cell transplant recipients and CAR-T cell recipients, (2) Incidence and outcome of HHV-6 encephalitis in patients who undergo allogeneic haploidentical HSCT, (3) Impact of pre-existing invasive aspergillosis on allogeneic stem cell transplantation (IPAT), (4) Real life management of antibiotic therapy in HSCT recipients.

PROSPECTIVE STUDIES STARTING SOON:

(1) Infections following CAR T-cell therapy, (2) Viral infections after unmanipulated allo-HSCT in pediatric patients, (3) Central nervous system complications following hematopoietic stem cell transplantation.

- Per Ljungman (Sweden): Management strategies in the new adenovirus landscape
- Catherine Cordonnier (France): How to structure an effective HSCT vaccine programme

SPECIAL SESSION

(Saturday 29 august, time 13.30-13.45)

 Per Ljungman (Sweden): The challenge of COVID-19 for HSCT: EBMT recommendations and prospective registry study

IDWP E-POSTERS

Jan Styczynski: Use of letermovir in off-label indications: IDWP of EBMT retrospective study

Jaroslaw Dybko: Progressive Multifocal leukoencephalopathy (PML) after HCT – A retrospective study of IDWP

Christine Robin: Pneumocystis pneumonia after allogeneic HCT: a case-control study on risk factors, timing, and PCR use

Jose Luis Piñana: Upper and/or lower respiratory tract infection caused by human Coronavirus after allogeneic stem cell transplantation

Malgorzata Mikulska: Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents (DAAS) in HCT recipients – EBMT IDWP study

Joanna Drozd-Sokołowska: Tuberculosis after hematopoietic cell

MAJOR EDUCATIONAL COURSES 2019

6

8th European Conference on Infections in Leukemia and Hematopoietic Cell Transplantation – 21-22 September 2019, Sophie Antipolis, France.

(final recommendations available at www.ecil-leukaemia.com/resources.htm)

22nd Educational Course of the Infectious Diseases Working Party – 17-19 October 2019 in Krakow, Poland.



Key Publications 2019

VACCINATION OF PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES WHO DID NOT HAVE TRANSPLANTATIONS: GUIDELINES FROM THE 2017 EUROPEAN CONFERENCE ON INFECTIONS IN LEUKAEMIA (ECIL 7). Mikulska et al., Lancet Infect Dis. doi: 10.1016/S1473-3099(18)30601-7.


transplantation: Retrospective study of IDWP of EBMT

Emilan Snarski: Risk of infectious complications in adult patients after allogeneic HCT depending on the site of central venous catheter insertion – multicenter prospective study.

Moshe Yeshurun: Infection prevention practices among EBMT hematopoietic cell transplant centres: a Survey of the IDWP

Malgorzata Mikulska: HEV infection in HCT recipients – Retrospective study of IDWP of EBMT

Jan Styczynski: Adenovirus infections after HCT: Retrospective registry study of IDWP



VACCINATION OF HAEMOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: GUIDELINES OF THE 2017 EUROPEAN CONFERENCE ON INFECTIONS IN LEUKAEMIA (ECIL 7). Cordonnier et al., Lancet Infect Dis. doi: 10.1016/S1473-3099(18)30600-5.

GUIDELINES FOR THE MANAGEMENT OF CYTOMEGALOVIRUS INFECTION IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES AND AFTER STEM CELL TRANSPLANTATION FROM THE 2017 EUROPEAN CONFERENCE ON INFECTIONS IN LEUKAEMIA(ECIL 7). Ljungman et al., Lancet Infect Dis. doi: 10.1016/S1473-3099(19)30107-0.

GUIDELINES FROM THE 2017 EUROPEAN CONFERENCE ON INFECTIONS IN LEUKAEMIA FOR MANAGEMENT OF HHV-6 INFECTION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION. Ward et al., Haematologica. doi: 10.3324/haematol.2019.223073.

DEATH AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: CHANGES OVER CALENDAR YEAR TIME, INFECTIONS AND ASSOCIATED FACTORS. Styczynski et al. Bone Marrow Transplant. 2020 Jan;55(1):126-136. doi: 10.1038/s41409-019-0624-z.

A SURVEY ON INCIDENCE AND MANAGEMENT OF ADENOVIRUS INFECTION AFTER ALLOGENEIC HSCT. Cesaro et al., Bone Marrow Transplant. doi: 10.1038/s41409-018-0421-0.

Decrease in mortality after HCT in EBMT centers between 2002-2015 in comparison to 1980-2001 (Styczynski et al, Bone Marrow Transplant, 2019, open access).

Contact

For participation in, or information on IDWP studies, please contact the IDWP at the EBMT Data Office in Leiden, The Netherlands

<u>Rafael de la Camara</u> IDWP Chair

Dina Averbuch IDWP Secretary IDWP Data Office, Nina Knelange IDWP Study coordinator Idwp.ebmt@lumc.nl

www.ebmt.org #EBMT20Virtual